KANGHUI PHARMACEUTICAL(SH:603139) Xin Lang Cai Jing·2026-01-23 23:46Core Viewpoint - The company, Shaanxi Kanghui Pharmaceutical Co., Ltd., is expected to report a significant loss for the fiscal year 2025, with a projected net profit attributable to the parent company of approximately -327 million yuan [2][4]. Group 1: Performance Forecast - The performance forecast period is from January 1, 2025, to December 31, 2025 [3]. - The estimated net profit attributable to the parent company is projected to be around -327 million yuan [4]. - The estimated net profit, excluding non-recurring gains and losses, is expected to be approximately -208 million yuan [5]. Group 2: Previous Year Performance - In the same period last year, the total profit was -121.54 million yuan, with a net profit attributable to the parent company of -89.63 million yuan [7]. - The net profit, excluding non-recurring gains and losses, was -67.02 million yuan [7]. - The earnings per share for the previous year were -0.90 yuan [8]. Group 3: Reasons for Performance Decline - The primary reason for the expected loss is the suspension of operations at the company's subsidiary, Shaanxi Youbang Biomedical Technology Co., Ltd., which has filed for pre-restructuring [9]. - The company has made provisions for bad debts amounting to approximately 125 million yuan due to the subsidiary's situation, impacting the current performance [9]. - Additionally, the subsidiary's asset impairment and operational losses are estimated to affect the net profit by around 114 million yuan [9]. - The company has also faced a slight decline in sales revenue due to changes in the pharmaceutical industry policies and macroeconomic conditions, leading to increased operational costs [9].